Efficacy Analysis of Tigecycline-based Therapy and Polymyxin B-based Therapy in ICU Infection
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 800
- 试验地点
- 1
- 主要终点
- hospital mortality rate
研究概览
简要总结
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included.
To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis.
详细描述
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included. The four hospitals included the 1st-3th XiangYa Hospitals and Hunan Provincial People's Hospital. Organize the data.Patients with a course of treatment < 4 days and shedding were excluded.To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis. The chi-square test was used for the counting data, and the Mann-Whitney U test or Kruskal-Wallis H test was used for the measurement data. The significance value was adjusted by Bonferroni correction method for multiple tests, and the P was tested on both sides,P>0.05.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ICU patients receiving tigecycline or polymyxin B treatment;
- •Age 14-95, gender unlimited;
- •there are clear infections and strains;
- •The patient and/or his/her family agree to sign the informed consent voluntarily.
排除标准
- •Patients with treatment of less than 4 days;
- •patients with abscission;
- •Pregnant patients;
- •Patients with age < 14 years or > 95 years.
结局指标
主要结局
hospital mortality rate
时间窗: up to hospital discharge or die in hospital, up to 48 weeks(estimation).
Patients die in hospital or abandon treatment due to poor prognosis in hospital after treatment of tigecycline or polymyxin B
Bacterial clearance rate
时间窗: from the first day of the treatment of tigecycline or polymyxin B until to the end day, up to 8 weeks (estimation).
Bacterial clearance during treatment of tigecycline or polymyxin B
30d mortality rate
时间窗: up to the 30th day of the treatment of tigecycline or polymyxin B
Patients die after treatment of tigecycline or polymyxin B
次要结局
- The length of ICU stay(up to hospital discharge or die in hospital, up to 24 weeks (estimation).)
- VA days(up to hospital discharge or die in hospital, up to 48 weeks (estimation).)
- Hospitalization Cost(up to hospital discharge or die in hospital, up to 48 weeks (estimation).)
- The length of hospital stay(up to hospital discharge or die in hospital, up to 48 weeks (estimation).)
- serum creatinine(at the end day of the treatment of tigecycline or polymyxin B, up to 8 weeks (estimation).)
- MV days(up to hospital discharge or die in hospital, up to 48 weeks (estimation).)